Multiple Myeloma | Norton Healthcare

Indication: Multiple Myeloma

A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab (TJ011133) with or without Dexamethasone and in Combination with Anti-Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: AbbVie

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.